Acute kidney disease following cisplatin treatment in head and neck cancer: risk factors and survival impact
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background: Acute kidney disease (AKD), representing persistent or subacute kidney dysfunction occurring within 7 to 90 days, has emerged as an important framework bridging acute kidney injury (AKI) and chronic kidney disease. However, the occurrence and long-term clinical implications of AKD following cisplatin treatment in patients with head and neck squamous cell carcinoma (HNSCC) remain incompletely characterized. Methods: This study retrospectively analyzed patients with HNSCC treated with cisplatin using a longitudinal institutional clinical database. AKD was classified using the prespecified renal-function criteria applied in the original data-extraction algorithm during the 7-90-day period following cisplatin treatment. Clinical characteristics, AKD occurrence, and 5-year all-cause mortality were evaluated. Results: < 0.001) in univariable analysis. In the prespecified Cox model, the association between AKD and 5-year all-cause mortality did not reach statistical significance (adjusted HR, 1.09; 95% CI, 0.94-1.25). Only two ESKD events were observed during follow-up (0.1%). Conclusion: AKD was observed in 28.3% of this historical cohort of patients with HNSCC treated with cisplatin. Diabetes mellitus was more prevalent among patients with AKD in univariable analysis. The association between AKD and 5-year all-cause mortality did not reach statistical significance in the prespecified adjusted model, although the confidence interval did not exclude a clinically meaningful increase in risk.
Source: Frontiers in Medicine
Language: English
Subfield: Toxicology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7221748561